Related Experiment Video

Updated: Mar 25, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Higher plasma level of STIM1, OPG are correlated with stent restenosis after PCI

Haibin Li1, Zhian Jiang1, Xiangdong Liu2

  • 1Department of Cardiology, Third Affiliated Hospital of Hebei Medical University Hebei, China.

International Journal of Clinical and Experimental Medicine
|February 18, 2016
PubMed

Insights

Elevated plasma levels of Stromal Interaction Molecular 1 (STIM1) and Osteoprotegerin (OPG) are independent risk factors for in-stent restenosis after Percutaneous Coronary Intervention (PCI). This finding may help in controlling restenosis post-PCI.

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Interventional Cardiology

Background:

  • Percutaneous Coronary Intervention (PCI) is a primary treatment for Coronary Heart Disease (CHD).
  • In-stent restenosis (ISR) remains a significant clinical challenge following PCI procedures.
  • Identifying reliable biomarkers for ISR is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the correlation between plasma levels of Stromal Interaction Molecular 1 (STIM1) and Osteoprotegerin (OPG) and the occurrence of ISR after PCI.
  • To determine if STIM1 and OPG are independent risk factors for ISR.

Main Methods:

  • A cohort of 100 patients with CHD undergoing PCI were enrolled.
  • Plasma levels of STIM1 and OPG were measured before and after PCI.
  • Coronary angiography was performed 8 months post-PCI to assess for stenosis; patients were grouped based on restenosis presence.
  • Pearson correlation and multiple linear regression analyses were employed.

Main Results:

  • Plasma STIM1 and OPG levels showed no significant difference before PCI.
  • Patients with ISR (observation group) exhibited significantly higher plasma STIM1 and OPG levels post-PCI compared to those without ISR (control group).
  • High-sensitivity C-reactive protein (Hs-CRP) was also elevated in the ISR group.
  • Regression analysis identified Hs-CRP, STIM1, and OPG as independent risk factors for ISR.

Conclusions:

  • Elevated plasma STIM1 and OPG levels are independently associated with an increased risk of ISR in patients who have undergone PCI.
  • These findings suggest that STIM1 and OPG could serve as valuable biomarkers for predicting and managing restenosis after PCI.
Abstract

Keywords:
Percutaneous coronary intervention (PCI)high-sensitivity C-reactive protein (Hs-CRP)in stent restenosis (ISR)osteoprotegerin (OPG)stromal interaction molecular 1 (STIM1)

More Related Videos

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.4K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
948